Testosterone therapy with Testopel® and the Esoterix Laboratory assay: A CASE study

Testosterone therapy with Testopel® and the Esoterix Laboratory assay: A CASE study

We present a patient receiving Testopel® implants whose serum testosterone levels, as measured by a CDC certified assay, were accurately predicted by a multi-compartmental model. This is the first time a model has predicted measured serum testosterone levels within 4% of values calculated. To our kn...

Full description

Bibliographic Details
Main Authors: David Seitman, Joseph Fallon, Barry Kimmel
Format: Article
Language:English
Published: Elsevier 2021-09-01
Series:Urology Case Reports
Subjects:
Case report
Pharmacokinetics
Testosterone pellets
Testosterone replacement therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2214442021001546
id doaj-aea088a14a324898809080ef9242c39d
record_format Article
spelling doaj-aea088a14a324898809080ef9242c39d2021-08-02T04:40:17ZengElsevierUrology Case Reports2214-44202021-09-0138101714Testosterone therapy with Testopel® and the Esoterix Laboratory assay: A CASE studyDavid Seitman0Joseph Fallon1Barry Kimmel23 Cara Ct., Northfield, NJ, 08225, USA; Corresponding author.Department of Medicine at Rowan University in Sewell, NJ, USAChief of Division of Urology at Cape Regional Medical Center in Cape May, Courthouse, NJ, USAWe present a patient receiving Testopel® implants whose serum testosterone levels, as measured by a CDC certified assay, were accurately predicted by a multi-compartmental model. This is the first time a model has predicted measured serum testosterone levels within 4% of values calculated. To our knowledge, it was also the first time a pharmacokinetic model allowed patient targeted serum levels (peak/trough/average) to be reached within three months.http://www.sciencedirect.com/science/article/pii/S2214442021001546Case reportPharmacokineticsTestosterone pelletsTestosterone replacement therapy
collection DOAJ
language English
format Article
sources DOAJ
author David Seitman
Joseph Fallon
Barry Kimmel
spellingShingle David Seitman
Joseph Fallon
Barry Kimmel
Testosterone therapy with Testopel® and the Esoterix Laboratory assay: A CASE study
Urology Case Reports
Case report
Pharmacokinetics
Testosterone pellets
Testosterone replacement therapy
author_facet David Seitman
Joseph Fallon
Barry Kimmel
author_sort David Seitman
title Testosterone therapy with Testopel® and the Esoterix Laboratory assay: A CASE study
title_short Testosterone therapy with Testopel® and the Esoterix Laboratory assay: A CASE study
title_full Testosterone therapy with Testopel® and the Esoterix Laboratory assay: A CASE study
title_fullStr Testosterone therapy with Testopel® and the Esoterix Laboratory assay: A CASE study
title_full_unstemmed Testosterone therapy with Testopel® and the Esoterix Laboratory assay: A CASE study
title_sort testosterone therapy with testopel® and the esoterix laboratory assay: a case study
publisher Elsevier
series Urology Case Reports
issn 2214-4420
publishDate 2021-09-01
description We present a patient receiving Testopel® implants whose serum testosterone levels, as measured by a CDC certified assay, were accurately predicted by a multi-compartmental model. This is the first time a model has predicted measured serum testosterone levels within 4% of values calculated. To our knowledge, it was also the first time a pharmacokinetic model allowed patient targeted serum levels (peak/trough/average) to be reached within three months.
topic Case report
Pharmacokinetics
Testosterone pellets
Testosterone replacement therapy
url http://www.sciencedirect.com/science/article/pii/S2214442021001546
work_keys_str_mv AT davidseitman testosteronetherapywithtestopelandtheesoterixlaboratoryassayacasestudy
AT josephfallon testosteronetherapywithtestopelandtheesoterixlaboratoryassayacasestudy
AT barrykimmel testosteronetherapywithtestopelandtheesoterixlaboratoryassayacasestudy
_version_ 1721242098660802560

Similar Items